Ongoing clinical trials are examining the efficacy and feasibility of several systemic inhibitors of TGF-β, including ligand-neutralizing antibodies and inhibitors of TGF-β receptor type I kinase, to prevent the progression of kidney disease, including diabetic nephropathy. The gene discussed is TGFB1; the disease is diabetic kidney disease.